Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

Abstract: The present invention provides a microemulsion mixture, comprising a microemulsion and an active ingredient, wherein the microemulsion comprises a water phase composite, comprising a water solution and a moisturizer; an oil phase composite; and a surfactant composite; and the active ingredient is the substrate of cytochrome P450 3A4 enzyme. The microemulsion of the present invention inhibits the expression of the cytochrome P450 3A4 enzyme so as to improve the efficacy of the active ingredient in the microemulsion mixture. The present invention further provides a method of using the microemulsion mixture, a pharmaceutical microemulsion mixture comprising the microemulsion mixture, and the method for treating psoriasis comprising administering the microemulsion mixture to a subject in need thereof.

Abstract: A method of establishing a coronary artery disease (CAD) prediction model for CAD screening includes establishing a data set in a computer equipment; entering the data set and corresponding future CAD condition of asymptomatic individuals into a machine learning component; selecting a plurality of robust variables from the clinical data and the cardiovascular markers of the cardiovascular markers panel by using feature selection methods; establishing the CAD prediction model by using machine learning methods; uploading new clinical data and new results of the cardiovascular markers to the cloud-based platform when any asymptomatic individuals undergo the health examination, and performing calculation and analysis by the CAD prediction model; and notifying the asymptomatic individuals of having a high risk of encountering a CAD event or not in a certain period of follow-up time.

Abstract: A coronary artery disease (CAD) screening method includes 1) collecting clinical information of asymptomatic individuals and testing a plurality of samples of the individuals by using a cardiovascular markers panel including a plurality of cardiovascular markers; 2) entering the clinical information and the test results and the corresponding CAD states of the individuals into a machine learning platform; 3) selecting a plurality of roust variables from the clinical information and the cardiovascular markers of the cardiovascular markers panel by using feature selection methods; 4) using a machine learning algorithm embedded in the machine learning platform to establish a CAD prediction model; and 5) entering clinical information and sample data obtained by using the cardiovascular markers panel for an individual being screened into the CAD prediction model for calculation and analysis, thereby determining whether the individual being screened has CAD or not.

Abstract: An automatic sensing and warning device for placing an intravenous drip includes a transmitter unit, a blocking unit, a receiver unit, and a fixing device. The transmitter unit is attachable to an injection site on a patient's hand and is operable to transmit an identification signal. The receiver unit is arranged on the blocking unit and includes a drive circuit and a warning device. The fixing device supports the blocking unit and the receiver unit on the intravenous drip pole. The RF receiver is set at a predetermined vertical distance from a drip chamber and areas above and below the RF receiver are respectively defined as dangerous and safe areas. When the injection site is spaced from the drip chamber by a distance shorter than the predetermined distance, the RF receiver receives the identification signal from the RF transmitter and the drive circuit activates the warning device to issue warnings.